An interventional study of Early transcatheter edge-to-edge mitral valve repair (TEER). and MitraClip in Acute Mitral Regurgitation, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Recruiting at 32 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Mitral Valve Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Mitral Valve Insufficiency · Spain.
Among the 20 studies in Mitral Valve Insufficiency with a site in Spain, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 with no phase, reaches primary completion later than 7 of the 14 other live ones, and was the 15th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →11 of the 20 studies in Mitral Valve Insufficiency with a site in Spain are open now. Recruiting first, the newest first:
Germans Trias i Pujol Hospital · Sites in Spain
Ages 18–95
Shanghai Shenqi Medical Technology Co., Ltd · Sites in Spain
Ages 18+
4C Medical Technologies, Inc. · Sites in Spain, United States, Canada and 4 more countries
Ages 18+
Medtronic Cardiovascular · Sites in Spain, Denmark, France and 5 more countries
Ages 18+
LMU Klinikum · Sites in Spain, Austria, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 250 is above the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 204 across the 12 interventional studies, 775 across the 8 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 20 have an industry lead sponsor. The 10 most frequent:
Fundación para la Investigación Biosanitaria del Principado de Asturias is the lead sponsor of 13 studies on the registry; 6 are open to participants now.
Fundación para la Investigación Biosanitaria del Principado de Asturias has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Mitral Valve Insufficiency with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
| NCT06823700Shanghai Shenqi Medical Technology Co., LtdSafety and Effectiveness Study of SQ-Kyrin System for Functional Mitral Regurgitation in EU | 2026-12-31 |
| NCT06282042Fundación para la Investigación Biosanitaria del Principado de AsturiasEarly Transcatheter Mitral Valve Repair After Myocardial Infarction | 2027-06-16 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Mitral Valve Insufficiency with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To explore the impact of early transcatheter edge-to-edge repair of acute functional mitral regurgitation after myocardial infarction on the combined incidence of death and heart-failure associated hospitalisations at one-year follow-up, and quality of life and LV remodelling at two-year follow-up.
Prospective, multicentre, randomised, open-label, comparative effectiveness clinical trial for the treatment of clinically significant functional mitral regurgitation within 60 days after acute myocardial infarction, who are treated per standard of care and who have been determined by the site's local heart team as inappropriate or too high risk for mitral valve surgery.
Eligible subjects will be randomized in a 1:1 ratio to the MitraClip device (intervention group) or to no MitraClip device (Control group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Early transcatheter edge-to-edge mitral valve repair (TEER) plus optimal medical treatment
Procedure: Early transcatheter edge-to-edge mitral valve repair (TEER). · Device: MitraClip · Other: Optimal medical treatment
Optimal medical treatment
Other: Optimal medical treatment
TEER will be planned and performed as soon as possible, but within 60 days after index myocardial infarction, and within 30 days of randomisation using the MitraClip device.
MitraClip
Optimal medical treatment
All-cause death or Cumulative Heart Failure hospitalizations
Composite of 1. All-cause death 2. Cumulative Heart Failure hospitalizations
Time frame: 12 months
Plan to share: No
Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 29 months after the start.
Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 29 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Investigación Biosanitaria del Principado de Asturias